Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

52 results about "UBE3A" patented technology

Ubiquitin-protein ligase E3A (UBE3A) also known as E6AP ubiquitin-protein ligase (E6AP) is an enzyme that in humans is encoded by the UBE3A gene. This enzyme is involved in targeting proteins for degradation within cells.

Methods for modulating UBE3a-ats

PCT designated stage expiredWO2025101991A1Organic active ingredientsDrug compositionsUbiquitin-Protein Ligase E3ABiochemistry
Provided are methods of administering ION582 for reducing the amount or activity of UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A) in a cell or subject, and in certain instances increasing the expression of paternal UBE3A and the amount of UBE3A protein in the cell or subject. In certain embodiments, the subject has Angelman syndrome (AS).
Owner:IONIS PHARMACEUTICALS INC

Methods and compositions for increasing expression of UBE3a

PCT designated stage expiredWO2025101533A1DNA/RNA fragmentationNucleotideNucleotide sequencing
This disclosure provides, among other things, methods and compositions for increasing UBE3A expression in cells, particularly cells that express UBE3A-ATS. In some embodiments, this disclosure provides nucleic acid cassettes that encode RNAs that are complementary to one or more regions of UBE3A-ATS. In some embodiments, the disclosure provides a nucleic acid cassette comprising a transgene encoding an RNA that binds a nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15.
Owner:ENCODED THERAPEUTICS INC

Oligonucleotides for inducing paternal UBE3a expression

The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
Owner:OHB PEDIATRICS LTD

UBE3A genes and expression cassettes and their use

This invention relates to polynucleotides comprising UBE3A open reading frame (ORF) sequences, vectors comprising the same, and methods of using the same for delivery of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of a UBE3A gene or aberrant activity of a UBE3A gene product in the subject, such as Angelman Syndrome.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL

Compositions and methods for crispr / CAS9 based reactivation of human angelman syndrome

PCT designated stageWO2026006542A2Organic active ingredientsSpecial deliveryGenomic mutationGenetics
Systems and methods for highly-effective CRISPR-Cas based genomic editing within human chromosome 15q11-q13 have been developed as therapeutic interventions for Angelman Syndrome (AS). Selective single guide RNA molecules (sgRNAs) that impart enhanced CRISPR-Cas editing of genomic mutations associated with Angelman Syndrome in human cells are described. The engineered sgRNAs induce activity of non-pathogenic, paternal UBE3A alleles to reduce, reverse and / or prevent the causative neurodevelopmental defects of AS in a subject in need thereof. Compositions and methods of engineered crRNAs, sgRNAs thereof and ribonucleoprotein (RNP) complexes thereof are provided for enhanced genomic engineering with increased on-off target specificity and on-target editing efficacy for treatment of AS.
Owner:YALE UNIVERSITY

Oligonucleotides for inducing paternal UBE3a expression

PendingJP2025024060AOrganic active ingredientsNervous disorderUbiquitin-Protein LigasesNeural cell
To provide oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons.SOLUTION: The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.SELECTED DRAWING: Figure 1
Owner:F HOFFMANN LA ROCHE & CO AG

shRNA targeting the SNORD115 locus to restore paternally derived UBE3A gene expression in Angelman syndrome

Provided herein are compositions and methods for activating expression from the paternally inherited allele of UBE3A in Angelman syndrome using viral vector delivery of short hairpin RNA. Provided herein are compositions and methods for reducing or eliminating expression of SNORD115 and UBE3A-ATS in Angelman syndrome using viral vector delivery of short hairpin RNA.
Owner:UNIV OF CONNECTICUT +1

Angelman syndrome antisense treatment

ActiveUS12180480B2Organic active ingredientsSugar derivativesNeurophysinsUbiquitin-Protein Ligases
Disclosed herein are antisense oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA at the 5′-end of UBE3A-AS, which is downstream of SNORD115-45 snoRNA. Also disclosed are pharmaceutical compositions and methods for treatment of Angelman syndrome.
Owner:TEXAS A&M UNIVERSITY

Compositions and methods for treating conditions associated with overexpression of UBE3A

This application provides antisense nucleic acid compounds that reduce the levels of certain nutrients in neurons of the central nervous system. UBE3A This application also provides compositions comprising antisense nucleic acid compounds and their application in the prevention or treatment of overdose in subjects. UBE3A Use in methods related to mRNA and / or UBE3A peptide levels.
Owner:ULTRAGENYX PHARMACEUTICAL INC

UBE3a for treatment of angelman syndrome

PendingJP2025148578ANervous disorderPeptide/protein ingredientsSevere speech impairmentDisease
To provide UBE3A for the treatment of Angelman syndrome.SOLUTION: Angelman syndrome is a genetic neurological disorder with characteristics including delayed development, intellectual disability, severe speech impairment, and problems with movement and balance. Provided herein are polynucleotides, vectors, polypeptides, cells, compositions, kits and methods to treat Angelman syndrome. Provided herein are, for example, the following: a recombinant polynucleotide encoding a Ubiquitin Protein Ligase E3A (Ube3a) polypeptide or protein or a biological equivalent thereof, the Ube3a polypeptide or protein or a biological equivalent thereof comprising one or more naturally occurring or non-naturally occurring glycosylation sites.SELECTED DRAWING: None
Owner:RGT UNIV OF CALIFORNIA

Angelman syndrome antisense treatment

Disclosed herein are antisense oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA at the 5'-end of UBE3A-AS, which is downstream of SNORD115-45 snoRNA. Also disclosed are pharmaceutical compositions and methods for treatment of Angelman syndrome.
Owner:TEXAS A&M UNIVERSITY

Antisense oligonucleotide for inducing expression enhancement by targeting UBE3a, and use thereof

Disclosed are: an antisense oligonucleotide, which targets the 5'- UTR of UBE3A, for inducing enhanced expression of UBE3A; and use thereof for treating diseases associated with UBE3A deficiency. The antisense oligonucleotide induces splicing to increase the production of productive isoforms of mRNA that do not include regions that inhibit translation of UBE3A, thereby increasing the expression level of UBE3A, and thus can treat or alleviate diseases or symptoms caused by UBE3A deficiency in individuals.
Owner:KOREA ADVANCED INST OF SCI & TECH

Compositions and methods for treating conditions associated with UBE3a overexpression

This application provides antisense nucleic acid compounds that reduce UBE3A mRNA levels and / or UBE3A polypeptide levels in central nervous system neurons, thereby alleviating effects and symptoms caused by excess UBE3A levels. The application further provides compositions comprising antisense nucleic acid compounds and their use in methods of preventing or treating conditions associated with excess UBE3A mRNA and / or UBE3A polypeptide levels in a subject.
Owner:ULTRAGENYX PHARMACEUTICAL INC

E6 protein mutant serving as E3 ubiquitin ligase ligand and activating factor and application of E6 protein mutant

The invention discloses an E6 protein mutant serving as an E3 ubiquitin ligase ligand and an activating factor and application of the E6 protein mutant, and relates to the technical field of biological medicine. The amino acid sequence of the E6 protein mutant is as shown in SEQ ID NO. 1. According to the invention, E6 protein is modified to obtain an E6 protein mutant, and the E6 protein mutant is used as a novel E3 ubiquitin ligase ligand and an activating factor and is applied to construction of a protein degradation targeting chimera. Compared with the prior art, the invention provides a new tool for the PROTAC technology. The E6 protein mutant serving as an E3 ubiquitin ligase ligand and an activating factor can be combined with ubiquitin protein ligase UBE3A / E6AP in a targeted mode, and after the E6 protein mutant is combined with a target protein ligand of target protein, formed fusion protein can activate the ubiquitin protein ligase UBE3A / E6AP and efficiently degrade the target protein in a targeted mode.
Owner:SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY

Method for targeting UBE3a allele to establish animal model of angelman syndrome and use thereof

The present invention provides a method for targeting a maternal UBE3A allele to establish an animal model of Angelman syndrome and use thereof. By means of extensive and in-depth research and screening of the sequences of primate genome UBE3A genes, a target suitable for genetic engineering is obtained: an intron upstream of and / or an intron downstream of exon 5 of a maternal UBE3A gene. An animal model of Angelman syndrome can be obtained by performing downregulation targeting the target. The animal model has a stable and controllable state and a typical disease phenotype, which is conducive to observation.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI

ShRNA targeting UBE3A-ATS to restore paternal UBE3A gene expression in happy puppet syndrome

PendingCN119053703AOrganic active ingredientsSugar derivativesHappy puppet syndromeGenetic alleles
Provided herein are compositions and methods for activating expression of paternal genetic alleles of UBE3A in happy puppet syndrome using viral vector delivery of short hairpin RNA. Provided herein are compositions and methods for reducing or eliminating the expression of UBE3A-ATS in happy puppet syndrome using viral vector delivery of short hairpin RNA.
Owner:UNIV OF CONNECTICUT +1

Compositions and methods for treating conditions associated with UBE3a overexpression

This application provides antisense nucleic acid compounds that reduce UBE3A mRNA levels and / or UBE3A polypeptide levels in central nervous system neurons, thereby alleviating effects and symptoms caused by excess UBE3A levels. The application further provides compositions comprising antisense nucleic acid compounds and their use in methods of preventing or treating conditions associated with excess UBE3A mRNA and / or UBE3A polypeptide levels in a subject.
Owner:ULTRAGENYX PHARMACEUTICAL INC

antisense oligonucleotide

PendingCN122663282ANucleotideGenetics
The present invention relates to an antisense oligonucleotide, wherein the antisense oligonucleotide is 8 to 40 nucleotides in length and comprises a contiguous nucleotide sequence of at least 8 nucleotides in length which is complementary to a region of a UBE3A pre-mRNA transcript, wherein the UBE3A pre-mRNA transcript comprises a repeat of at least 8 nucleotides and the contiguous nucleotide sequence is complementary to at least 8 nucleotides in each repeat.
Owner:F HOFFMANN LA ROCHE & CO AG

Methods and compositions for increasing expression of UBE3a

This disclosure provides, among other things, methods and compositions for increasing UBE3A expression in cells, particularly cells that express UBE3A-ATS. In some embodiments, this disclosure provides nucleic acid cassettes that encode RNAs that are complementary to one or more regions of UBE3A-ATS. The methods and compositions may be used to induce expression of paternal UBE3A in a cell where expression of paternal UBE3A is suppressed, e.g., by silencing.
Owner:ENCODED THERAPEUTICS INC

Angelman syndrome antisense treatment

Disclosed herein are antisense oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA at the 5′-end of UBE3A-AS, which is downstream of SNORD115-45 snoRNA. Also disclosed are pharmaceutical compositions and methods for treatment of Angelman syndrome.
Owner:TEXAS A&M UNIVERSITY

Antisense oligonucleotide

PCT designated stage expiredWO2025132962A3Organic active ingredientsPolymorphism usesNucleotideGenetics
The present invention relates to an antisense oligonucleotide, wherein the antisense oligonucleotide is 8 to 40 nucleotides in length and comprises a contiguous nucleotide sequence of at least 8 nucleotides in length which is complementary to a region of a UBE3A pre-mRNA transcript, wherein the UBE3A pre-mRNA transcript comprises a duplication of at least 8 nucleotides and the contiguous nucleotide sequence is complementary to at least 8 nucleotides in each duplication.
Owner:F HOFFMANN LA ROCHE & CO AG +1

Compositions and methods for restoring paternal UBE3A gene expression in human happy puppet syndrome

PendingCN119592561AOrganic active ingredientsNervous disorderHappy puppet syndromeGenetic alleles
The present application relates to compositions and methods for restoring paternal UBE3A gene expression in human happy puppet syndrome. The present invention relates to compositions and methods for activating paternal genetic allele expression of UBE3A in human happy puppet syndrome (Angelman's Syndrome) neurons using viral vector delivery of short hairpin RNA, ribozyme, and / or micro RNA.
Owner:UNIV OF CONNECTICUT

Human-targeted zinc finger protein to treat angelman syndrome

PCT designated stage expiredWO2025076201A1Fusion with DNA-binding domainNervous disorderDiseasePhysiology
In Angelman syndrome (AS), loss of UBE3A protein in the brain is typically due to mutation or deletion of the maternal UBE3A allele. Due to genetic imprinting, the paternal UBE3A allele is present but epigenetically silenced by an antisense transcript. As disclosed herein, activation of this paternal allele of UBE3A has great promise to treat the underlying causes of this disorder and bring meaningful improvements to children. Disclosed herein is a programable Artificial Transcription Activator (ATF) that can silence expression of the UBE3A transcript. Also disclosed herein is a method of treating Angelman Syndrome in a subject, the method involving administering to the subject an effective amount of a pharmaceutical composition comprising one or more AAV vectors containing a polynucleotide encoding the disclosed ATF.
Owner:RGT UNIV OF CALIFORNIA

Compounds and Methods for Modulating UBE3A-ATS

PendingUS20260132402A9Sugar derivativesScreening processSpeech disorderUbiquitin-Protein Ligases
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A) in a cell or subject, and in certain instances increasing the expression of paternal UBE3A and the amount of UBE3A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurogenetic disorder. Such symptoms and hallmarks include developmental delays, ataxia, speech impairment, sleep problems, seizures, and EEG abnormalities. Such neurogenetic disorders include Angelman Syndrome.
Owner:IONIS PHARMACEUTICALS INC

Method for establishing angel syndrome animal model by targeting UBE3A allele and application

The invention provides a method for establishing an angel syndrome animal model by targeting a UBE3A maternal allele and application. On the basis of extensive and in-depth research and screening of sequences of primate genome UBE3A genes, a target suitable for gene modification is obtained: an upstream intron and / or a downstream intron of maternal UBE3A gene exon5, and an angel syndrome animal model can be obtained by targeting the target to implement down regulation. The animal model is stable and controllable in state, typical in disease phenotype and easy to observe.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI

Genetic biomarkers for identifying PTSD and major depression

The present invention provides a method for detecting post-traumatic stress disorder (PTSD) in a human subject, the method comprising: obtaining a cell sample obtained from the human subject; measuring a test gene expression level of one or more PTSD-related genes from the cell sample with a first computer program executed on a computer, in which the PTSD-related genes are selected from the group consisting of TSPAN5, HIST1H2AE, UBE3A, GPX4, EPB42, SLC4A1, NDUFA1, HIST1HEH, ELOVL7, ALES, COMPT, PDZK1IP1, ITGA2B, CYP4F3, EPB41L3, PRDM1, RP-11-449P15.1, FAS, TUBB2A, and JAM3; comparing the tested PTSD-related expression level with one or more control gene expression levels with a second computer program executing on the computer; determining differential expression of the one or more tested PTSD related genes; and determining a positive detection result of the PTSD.
Owner:CHUANGJINOMIX HEALTH CO

Genetic biomarkers for identifying PTSD and major depression

Provided herein is a method for detecting post-traumatic stress disorder (PTSD) in a human subject, the method comprising: obtaining a cell sample obtained from the human subject; measuring a test gene expression level of one or more PTSD-related genes from the cell sample using a first computer program executed on a computer, wherein the PTSD-related genes are selected from the group consisting of TSPAN5, HIST1H2AE, UBE3A, GPX4, EPB42, SLC4A1, NDUFAC HISTIHEH, ELOVL7, ALES, COMPT, PDZK IPI, ITGA2B, CYP4F3, EPB41L3, PRDM1, RP-II-449PI5.I, FAS, TUBB2A, and JAM3; comparing the test PTSD-related expression level to one or more control gene expression levels using a second computer program executed on a computer; determining differential expression of the one or more test PTSD-related genes; and determining a positive detection of PTSD.
Owner:TRUGENOMIX HEALTH INC